For the most up to date list of publications, check out my Google Scholar page.

Peer-reviewed Publications

  1. K Whiting, EV Robilotti, A Lucca, C Poon, K Jani, T McMillen, S Freeswick, and others (2022). “Effectiveness of mRNA booster vaccine among health Care workers in New York City during the omicron surge, December 2021-January 2022.” Clinical Microbiology and Infection,

  2. K Whiting, EV Robilotti, A Lucca, C Poon, R Guest, T McMillen, K Jani, and others (2021). “Clinical and Genomic Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Infections in mRNA Vaccinated Health Care Personnel in New York City.” Clinical Infectious Diseases,

  3. K Whiting, N Almassi, A Toubaji, AT Lenis, EJ Jordan, H Won, and others (2022). “Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.” JCO Precision Oncology, 6, e2100392

  4. SA Funt, M Lattanzi, K Whiting, H Al-Ahmadie, C Quinlan, MY Teo, and others (2022). “Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: A multicenter, single-arm, phase II trial.” Journal of Clinical Oncology, 40 (12), 1312-1322

  5. H Furberg, S Petruzella, K Whiting, E Stein, I Orlow, J Kenney, and others (2022). “Association of biochemically verified post-diagnosis smoking and nonmuscle-invasive bladder cancer recurrence risk.” The Journal of Urology, 207 (6), 1200-1206

  6. JE Mandel, DH Kim, H Yarmohammadi, E Ziv, ML Keohan, SP D’Angelo, K Whiting, and others (2022). “Percutaneous cryoablation provides disease control for extra-abdominal desmoid-type fibromatosis comparable with surgical resection.” Annals of Surgical Oncology, 29 (1), 640-648

  7. R Perez-Johnston, JA Araujo-Filho, JG Connolly, R Caso, K Whiting, and others (2022). “CT-based radiogenomic analysis of clinical stage I lung adenocarcinoma with histopathologic features and oncologic outcomes.” Radiology, 303 (3), 664-672

  8. CM Stewart, L Michaud, K Whiting, R Nakajima, C Nichols, S De Frank, and others (2022). “Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA MonitoringBuparlisib and Ibrutinib in Non ….” Clinical Cancer Research, 28 (1), 45-56

  9. EJ Pietzak, K Whiting, P Srinivasan, C Bandlamudi, A Khurram, V Joseph, and others (2022). “Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer.” Clinical Cancer Research,

  10. MA Mallory, K Whiting, A Park, M Gönen, E Gilbert, TA King, ML Pilewskie (2022). “Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ.” Breast Cancer Research and Treatment, 1-12

  11. D Qualls, HYJ Lam, K Whiting, A Kumar, MJ Matasar, C Owens, C Nichols, and others (2022). “A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.” Blood advances, bloodadvances., 2021006555

  12. DD Sjoberg, K Whiting, M Curry, JA Lavery, J Larmarange (2021). “Reproducible Summary Tables with the gtsummary Package..” R Journal, 13 (1)

  13. S Petruzella, BH Bochner, J Kenney, K Whiting, K Sadeghi, N Benfante, and others (2021). “Examining the accuracy of self-reported smoking-related exposure among recently diagnosed nonmuscle invasive bladder cancer patients.” The Journal of Urology, 205 (5), 1321-1325

  14. M Sarfaty, K Whiting, MY Teo, CH Lee, V Peters, J Durocher, AM Regazzi, and others (2021). “A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract.” Cancer medicine, 10 (3), 1074-1083

  15. JM Mota, MY Teo, K Whiting, HA Li, AM Regazzi, CH Lee, SA Funt, and others (2021). “Pretreatment eosinophil counts in patients with advanced or metastatic urothelial carcinoma treated with anti-PD-1/PD-L1 checkpoint inhibitors.” Journal of Immunotherapy, 44 (7), 248-253

  16. PB Romesser, EJ Sherman, K Whiting, ML Ho, AR Shaha, MM Sabra, and others (2021). “Intensity‐modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial.” Cancer, 127 (22), 4161-4170

  17. A Alarcon Tomas, K Whiting, M Maloy, JD Ruiz, S Devlin, and others (2021). “The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+ selected allogeneic stem cell transplant.” Bone Marrow Transplantation, 56 (11), 2749-2754

  18. V McPherson, B Reardon, A Bhayankara, K Whiting (2021). “A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma (vol 126, pg 4532, 2020).” CANCER, 127 (13), 2376-2376

  19. E Mendelsohn, N Ross, AM White, K Whiting, C Basaraba, and others (2021). “A global repository of novel antimicrobial emergenc e events [version 2; peer review: 1 approved, 2 approved with.” ,

  20. MY Teo, JM Mota, K Whiting, HA Li, SA Funt, CH Lee, DB Solit, and others (2021). “Corrigendum re” Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and ….” European urology, 79 (5), e158-e159

  21. DD Sjoberg, M Curry, M Hannum, K Whiting, EC Zabor (2020). “Gtsummary: Presentation-ready data summary and analytic result tables. R package version 1.3. 5.” ,

  22. MY Teo, JM Mota, K Whiting, HA Li, SA Funt, CH Lee, DB Solit, and others (2020). “Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial ….” European urology, 78 (6), 907-915

  23. E Mendelsohn, N Ross, AM White, K Whiting, C Basaraba, and others (2020). “Extracting novel antimicrobial emergence events from scientific literature and medical reports.” F, F1000Research 9

  24. C Machalaba, T Allen, A Andre, B Arnold, N Breit, K Whiting, WB Karesh, and others (2018). “Digital Disease Detection for Health Security.” APHA’s, 2018 Annual Meeting & Expo (Nov. 10-Nov. 14)

  25. N Ross, A White, C Basaraba, B Watson, E Johnson, K Whiting, and others (2018). “Generating better macroecological data from literature: A case study of antimicrobial resistance emergence.” , 2018 ESA Annual Meeting (August 5–10)

  26. AG Huff, T Allen, K Whiting, F Williams, L Hunter, Z Gold, LC Madoff, and others (2017). “Biosurveillance: a systematic review of global infectious disease surveillance systems from 1900 to 2016..” Revue Scientifique et Technique (International Office of Epizootics), 36 (2 …

  27. A Huff, T Allen, K Whiting, N Breit, B Arnold (2016). “FLIRT-ing with Zika: a web application to predict the movement of infected travelers validated against the current Zika virus epidemic.” PLoS currents, 8

  28. AG Huff, N Breit, T Allen, K Whiting, C Kiley (2016). “Evaluation and verification of the global rapid identification of threats system for infectious diseases in textual data sources.” Interdisciplinary perspectives on infectious diseases, 2016

  29. A Huff, T Allen, K Whiting, B Arnold, N Breit, A Miessler (2016). “FLIRT, a web application to predict the movement of infected travelers validated against the current Zika virus epidemic.” International Journal of Infectious Diseases, 53, 97-98